ACHN Achillion Pharmaceuticals, Inc.

+0  (3%)
Previous Close 3.54
Open 3.55
Price To book 1.21
Market Cap 500.40M
Shares 136,721,000
Volume 974,095
Short Ratio 7.20
Av. Daily Volume 1,371,490

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a ongoing.
Hepatitis C (HCV)
Phase 2 initiation announced April 6, 2017. Interim data due 2Q 2017.
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 2b trial initiation announced November 30, 2016.
JNJ-4178 - OMEGA-1
Hepatitis C (HCV)

Latest News

  1. Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178
  2. If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss
  3. Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria
  4. Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Corbus Pharmaceuticals
  5. Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : March 30, 2017
  6. Why Is Achillion (ACHN) Down 11.3% Since the Last Earnings Report?
  7. USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors
  8. Achillion Pharmaceuticals, Inc. :ACHN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  9. Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?
  10. These 5 Stocks Under $10 Could Explode Up Soon
  11. Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London
  12. Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss
  13. Biotech Movers: Cempra Flys High On Phase Three Results
  14. Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : February 24, 2017
  15. Achillion reports 4Q loss
  16. Biotech's Rally Continues to Build in 2017: Today's Reports on Achillion Pharmaceuticals and Pulmatrix
  17. Achillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference
  18. Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen